BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32923121)

  • 21. Low Pretreatment Lymphocyte-Monocyte Ratio and High Platelet-Lymphocyte Ratio Indicate Poor Cancer Outcome in Early Tongue Cancer.
    Ong HS; Gokavarapu S; Wang LZ; Tian Z; Zhang CP
    J Oral Maxillofac Surg; 2017 Aug; 75(8):1762-1774. PubMed ID: 28063763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count.
    Dhakal HP; Bassarova A; Naume B; Synnestvedt M; Borgen E; Kaaresen R; Schlichting E; Wiedswang G; Giercksky KE; Nesland JM
    Histol Histopathol; 2009 Aug; 24(8):1049-59. PubMed ID: 19554512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
    Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
    Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
    Bidard FC; Michiels S; Riethdorf S; Mueller V; Esserman LJ; Lucci A; Naume B; Horiguchi J; Gisbert-Criado R; Sleijfer S; Toi M; Garcia-Saenz JA; Hartkopf A; Generali D; Rothé F; Smerage J; Muinelo-Romay L; Stebbing J; Viens P; Magbanua MJM; Hall CS; Engebraaten O; Takata D; Vidal-Martínez J; Onstenk W; Fujisawa N; Diaz-Rubio E; Taran FA; Cappelletti MR; Ignatiadis M; Proudhon C; Wolf DM; Bauldry JB; Borgen E; Nagaoka R; Carañana V; Kraan J; Maestro M; Brucker SY; Weber K; Reyal F; Amara D; Karhade MG; Mathiesen RR; Tokiniwa H; Llombart-Cussac A; Meddis A; Blanche P; d'Hollander K; Cottu P; Park JW; Loibl S; Latouche A; Pierga JY; Pantel K
    J Natl Cancer Inst; 2018 Jun; 110(6):560-567. PubMed ID: 29659933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multiple breast cancer stem cell model to predict recurrence of T
    Qiu Y; Wang L; Zhong X; Li L; Chen F; Xiao L; Liu F; Fu B; Zheng H; Ye F; Bu H
    BMC Cancer; 2019 Jul; 19(1):729. PubMed ID: 31340763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis.
    LeVasseur N; Sun J; Gondara L; Diocee R; Speers C; Lohrisch C; Chia S
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):529-536. PubMed ID: 31741041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
    Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita T; Yamamoto Y; Ohno S; Toi M
    Breast Cancer Res Treat; 2017 Jun; 163(3):545-554. PubMed ID: 28337663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Survival Outcomes Among Patients With Breast Cancer With Distant vs Ipsilateral Supraclavicular Lymph Node Metastases.
    Pan H; Wang H; Qian M; Mao X; Shi G; Ma G; Yu M; Xie H; Ling L; Ding Q; Zhang K; Wang S; Zhou W
    JAMA Netw Open; 2021 Mar; 4(3):e211809. PubMed ID: 33724394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
    Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor.
    Blancas I; García-Puche JL; Bermejo B; Hanrahan EO; Monteagudo C; Martínez-Agulló A; Rouzier R; Hennessy BT; Valero V; Lluch A
    Ann Oncol; 2006 Nov; 17(11):1644-9. PubMed ID: 16873428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
    Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study.
    Frisk G; Ekberg S; Lidbrink E; Eloranta S; Sund M; Fredriksson I; Lambe M; Smedby KE
    Breast Cancer Res; 2018 Nov; 20(1):142. PubMed ID: 30458873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery.
    Forget P; Machiels JP; Coulie PG; Berliere M; Poncelet AJ; Tombal B; Stainier A; Legrand C; Canon JL; Kremer Y; De Kock M
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S650-60. PubMed ID: 23884751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients.
    Mostert B; Sieuwerts AM; Kraan J; Bolt-de Vries J; van der Spoel P; van Galen A; Peeters DJ; Dirix LY; Seynaeve CM; Jager A; de Jongh FE; Hamberg P; Stouthard JM; Kehrer DF; Look MP; Smid M; Gratama JW; Foekens JA; Martens JW; Sleijfer S
    Ann Oncol; 2015 Mar; 26(3):510-6. PubMed ID: 25471333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals.
    Guo W; Lu X; Liu Q; Zhang T; Li P; Qiao W; Deng M
    Cancer Med; 2019 Aug; 8(9):4135-4148. PubMed ID: 31197958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients.
    de Kruijf EM; Engels CC; van de Water W; Bastiaannet E; Smit VT; van de Velde CJ; Liefers GJ; Kuppen PJ
    Breast Cancer Res Treat; 2013 Nov; 142(2):355-64. PubMed ID: 24197659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.